Publication: Utilización de bifosfonatos en oncología
Loading...
Official URL
Full text at PDC
Publication Date
2015-06
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
INTRODUCCIÓN: La afectación ósea es una complicación común a muchos tipos de cánceres. La aparición de metástasis óseas puede producir otras complicaciones como dolor, fracturas o compresión medular, que contribuyen a una peor calidad de vida del enfermo y a su muerte. Los bifosfonatos (BFs) son un grupo terapéutico que han sido usados durante décadas para tratar diversos problemas óseos relacionados con la actividad de los osteoclastos. OBJETIVO: En el presente trabajo se realiza una revisión bibliográfica para conocer el uso de estos fármacos en oncología y sus perspectivas de futuro. MATERIAL Y MÉTODOS: Se ha realizado una búsqueda de fuentes primarias y terciarias en bases de datos de internet, como PubMed o Google Académico. RESULTADOS: Los BFs se emplean en el tratamiento de las complicaciones óseas y/o la prevención de metástasis en cáncer de mama, próstata, pulmón y otros tumores sólidos, así como en mieloma múltiple. Son empleados también en el tratamiento de la hipercalcemia asociada a cáncer y muestran efectos antitumorales per se que contribuyen a un sinergismo con la terapia habitual de éstos cánceres. CONCLUSIONES: Aunque son numerosas las evidencias, su uso es incierto. Es un grupo terapéutico que debe ser investigado, pues son aún muchos los aspectos que se desconocen sobre ellos.
INTRODUCTION: Bone affectation is a complication common to many types of cancers. Bone metastases apparition may produce other complications, such as pain, fractures or medular compression, which contribute to patient's quality of life deterioration and death. Bisphosphonates (BPs) are a therapeutical group that had been used for decades to treat diverse bone problems related to osteoclast activity. OBJECTIVE: In the present report, a bibliographical research on the use of these drugs in oncology has been done, as well as on its future perspectives. MATERIAL AND METHODS: online databases of primary and tertiary sources, like PubMed or Scholar Google, were used in this report. RESULTS: BFs are used on bone complications and/or bone metastases prevention treatment in breast, prostate and lung cancer and other solid tumors, as well as multiple myeloma. They are also used on cancer related hypercalcemia treatment and they appear to have intrinsically antitumor effects, which contribute to current anticancer therapy synergy. CONCLUSION: Despite of many evidences existance, use of BFs is uncertain. This therapeutical group may be deeply investigated, as many aspects of these drugs are still unknown.
INTRODUCTION: Bone affectation is a complication common to many types of cancers. Bone metastases apparition may produce other complications, such as pain, fractures or medular compression, which contribute to patient's quality of life deterioration and death. Bisphosphonates (BPs) are a therapeutical group that had been used for decades to treat diverse bone problems related to osteoclast activity. OBJECTIVE: In the present report, a bibliographical research on the use of these drugs in oncology has been done, as well as on its future perspectives. MATERIAL AND METHODS: online databases of primary and tertiary sources, like PubMed or Scholar Google, were used in this report. RESULTS: BFs are used on bone complications and/or bone metastases prevention treatment in breast, prostate and lung cancer and other solid tumors, as well as multiple myeloma. They are also used on cancer related hypercalcemia treatment and they appear to have intrinsically antitumor effects, which contribute to current anticancer therapy synergy. CONCLUSION: Despite of many evidences existance, use of BFs is uncertain. This therapeutical group may be deeply investigated, as many aspects of these drugs are still unknown.